Key Drivers
- Thin Margins
- Strong Cash Flow
- Negative Equity
AIAI Summary
McKesson should be viewed less as a defensive distributor and more as a high free-cash-flow platform whose upside now depends on sustaining specialty/oncology growth and executing the Medical-Surgical separation cleanly, because thin margins and a fragile balance sheet leave little cushion for reimbursement or execution missteps.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Thin Margins
- •Strong Cash Flow
- •Negative Equity
MCK is a cash-generating giant with strong free cash flow and efficient turnover, but its very thin margins, negative working capital, and negative equity make the balance sheet the main risk.
Price Behavior
Key Price Behavior Insights:
- •Trend Rebound
- •Support Holding
- •Resistance Capped
Over the last month, MCK is up about 6% and has rebounded off $744–$748 support, but repeated swings and $790–$791 resistance still make the setup cautious.
Sharp drop from the
Sentiment & News
Key News Insights:
- •Style-score strength
- •Earnings tailwind
- •Share-price volatility
McKesson is drawing broad favorable momentum, value, and growth coverage, with earnings supported by specialty pharma and oncology trends despite near-term share weakness and execution risks.
The news flow is mildly positive for McKesson, reinforcing a constructive investment case while near-term trading may stay choppy
Similar Companies in Healthcare
Other companies in the same sector with AI ratings